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A BST R A C T
OBJECTIVE: The objective of this selected EBM review is to determine whether or not
the injection of botulinum toxin improves symptoms in patients with gastroparesis.
STUDY DESIGN: Review of two published, double blind randomized controlled trials
and one published, open label pilot study were used for this review, which were found on
PubMed.
OUTCOMES MEASURED: The outcome was the change in gastroparesis-associated
symptoms, which was measured using the Gastroparesis Cardinal Scale Index (GCSI)
and Gastroparesis Questionnaire. In the two double blind, randomized controlled trials by
Arts et al. and Friendenberg et al., symptoms were quantified using the GCSI before and
after the injection. Each of the 9 different gastroparesis-associated symptoms (nausea,
regurgitation, vomiting, fullness, early satiety, postprandial fullness, loss of appetite,
bloating and swollen abdomen) were graded from 0 (none) -5 (very severe), with higher
scores indicating higher severity of symptoms. The total GCSI score was calculated by
adding all individual symptoms severity scores. In the open-label pilot study conducted
by Miller et al., the Gastroparesis Questionnaire was used to grade eight symptoms on a
5-point scale from 0 (none) to 4 (extreme). A total symptom score was determined as the
sum of each the eight graded symptoms, with a maximum of 32.
RESULTS: In the study by Arts et al, symptoms improved significantly after the initial
injection of saline or botulinum toxin. No additional improvement occurred after the
second injection. In the study by Friedenberg et al, the group receiving botulinum toxin
showed improvement in symptoms, however, it was not greater than the placebo group.
In the study by Miller et al, symptom scores improved with botulinum toxin injection.
CONCLUSION: The results of the two double blind, randomized controlled trials show
that the injection of botulinum toxin is not superior to placebo in improving symptoms of
gastroparesis. The results of the open-label pilot study indicate that botulinum toxin does
improve symptoms.
KEY WORDS: gastroparesis and botulinum toxin
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INTRODUCTION
Gastroparesis, or delayed gastric emptying, is a disorder that slows or stops the
movement of stomach contents to the small intestine.1 Normally, muscles of the stomach
contract to move food through the gastrointestinal tract.1 With gastroparesis, however,
food is not propelled properly and contents do not empty correctly; food leaves the
stomach slowly or does not move at all.1
This paper evaluates two double blind, randomized controlled trials, which
compare the efficacy of the injection of botulinum toxin for improving symptoms of
gastroparesis with placebo, and one open-label pilot study, which evaluates the ability of
botulinum toxin to mend symptoms. The consideration of improving symptoms of
gastroparesis is an important topic to discuss as the disorder is becoming increasingly
common; it affects 9.6 per 100,000 men and 38 per 100,000 women and occurs in 80% of
patients with dyspepsia.2,3 Additionally, over 40% of patients with diabetes have
gastroparesis.4 As the disorder becomes more prevalent, the cost of medical care for
gastroparesis increases as well. Although the cost in recent years is unknown, in 1998 the
average cost for hospitalization due to gastroparesis was $6,972 per patient per month.5
Furthermore, diabetic complications including gastroparesis totals $22.9 billion dollars.6
Hospital admissions are also elevated; admissions with gastroparesis as the main
diagnosis totaled 10,252 in 2004 and as the secondary diagnosis totaled 134,146 in 2004.6
Most cases of gastroparesis are idiopathic and therefore the cause is unknown.1
When the cause is able to be identified, diabetes is most common.1 Due to high levels of
blood glucose that is often found with diabetic patients, damage can occur to the vagus
nerve which leads to paralysis of stomach musculature.1 Other known causes include
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LQWHVWLQDOVXUJHU\DQGQHUYRXVV\VWHPGLVRUGHUVVXFKDV3DUNLQVRQ¶VGLVHDVHRUPXOWLSOH
sclerosis.1
Symptoms of gastroparesis include nausea, fullness after a small amount of food,
abdominal pain, abdominal bloating, and vomiting undigested food.1 Severity of the
symptoms is highly significant, as it is the basis of how physicians treat the disorder.1
Change in diet and careful nutrition is often the first attempt at managing gastroparesis.1
Smaller meals and low-fat, non-fibrous foods are frequently suggested.1 In addition,
medications can be used in management. Anti-emetics such as metoclopramide stimulate
stomach muscle contraction and help decrease nausea and vomiting.1 Antibiotics in low
doses, like erythromycin, may also improve gastric emptying.1 Possible side effects,
however, include nausea, vomiting, and abdominal cramps.1 If symptoms remain
uncontrolled, gastric electrical stimulation may be used. With this option, a batteryoperated device sends mild electrical pulses to stomach muscles to control nausea and
vomiting.1
Although the treatments listed above have been used to improve symptoms of
gastroparesis, no cure exists. The proposed method of botulinum toxin injection has been
used as treatment by acting as nerve-blocking agent.1 The toxin is injected into the
pylorus, the sphincter between the stomach and duodenum. Botulinum toxin keeps the
pylorus open for longer periods of time which allows food content to be passed more
easily to the small intestine and as a result, can lead to improvement of symptoms.1
Botulinum toxin is shown among the three trials to provide improvement in symptoms
but not superior in comparison to placebo.7,8,9
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OBJECTIVE
The objective of this systematic review is to determine whether or not the
injection of botulinum toxin improves symptoms in patients with gastroparesis.
METHODS
The studies included in this review are one double blind, placebo controlled
randomized controlled crossover trial, one double blind, placebo controlled randomized
controlled trial, and one open label pilot study. The population studied was men and
women with gastroparesis over the age of 18 years. The common intervention used
among all studies was botulinum toxin injection. In the study conducted by Arts et al.,
100 units (4 mL) of botulinum toxin was injected.7 In the second randomized controlled
trial, Friedenberg et al. used 200 units (5 mL) of botulinum toxin A.8 The open label pilot
study used a range of 80-100 units of botulinum toxin.9 The comparison intervention in
the two double blind, placebo controlled studies was equal volume saline solution.7,8
Outcomes measured included change in gastroparesis-associated symptoms and were
quantified using the Gastroparesis Cardinal Scale Index (GCSI) and Gastroparesis
Questionnaire. 7,8,9 The GCSI measured nausea, regurgitation, vomiting, fullness, early
satiety, postprandial fullness, loss of appetite, bloating and swollen abdomen and the
Gastroparesis Questionnaire measured postprandial fullness, early satiety, bloating,
epigastric discomfort, epigastric pain, postprandial nausea, belching after meals, and
vomiting.7,8,9
.H\ZRUGVXVHGLQVHDUFKHVIRUWKLVV\VWHPDWLFUHYLHZZHUH³JDVWURSDUHVLV´DQG
³ERWXOLQXPWR[LQ´$OODUWLFOHVZHUHSXEOLVKHGLQ(QJOLVKDQGLQSHHU-reviewed journals,
the American Journal of Gastroenterology and Ali mentary Pharmacology and
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Therapeutics.7,8,9 Articles were selected from PubMed and chosen based on relevance to
my clinical question and address of patient-oriented outcomes (POEMS). Inclusion
criteria included studies that were randomized controlled trials published after 1996 and
subjects that were older than 18 years old with diagnosed, documented gastroparesis.
Exclusion criteria consisted of patients under the age of 18 years old and studies specific
to one cause of gastroparesis. Summary statistics were reported using: p-values, numbers
needed to treat (NNT), and mean change from baseline.7,8,9
OUTCOMES
The outcome measured was change in gastroparesis-associated symptoms using
two questionnaires about these symptoms, the GCSI and Gastroparesis Questionnaire.
Using the GCSI, each of the nine different gastroparesis-associated symptoms (nausea,
regurgitation, vomiting, fullness, early satiety, postprandial fullness, loss of appetite,
bloating and swollen abdomen) was graded from 0 (none) to 5 (very severe), with higher
scores indicating higher severity of symptoms. The total GCSI score was calculated by
adding all individual symptoms severity scores, with a maximum score of 45.
In the crossover study by Arts et al., each patient completed the GCSI
questionnaire before the start of the study and one month after each injection of either
botulinum toxin or saline.7 Improvement in symptoms was based on mean change from
the baseline score.7 The study conducted by Friedenberg et al. also used the GCSI; a total
score of 27 was considered moderate to severe symptoms. A -point reduction at one
month after injection of the study drug was defined as improvement.8
In the open-label pilot study by Miller et al., subjects were compared using before
and after results of symptom scores based on the Gastroparesis Questionnaire, which
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measures eight symptoms on a 5-point scale graded from 0 (none) to 4 (extreme).9 A total
symptom score was determined as the sum of each the eight graded symptoms, with a
maximum of 32.9 Improvement in symptoms was based on mean change from baseline
score.
Table 1. Demographics & Characteristics of Included Studies
Study

Type

#
Pts
23

Age
(yrs)
>18

Inclusion
Criteria
Symptoms
suggestive of
gastroparesis,
established delayed
gastric emptying
for solids and
liquids

Arts
(2007)

Double
blind RCT
crossover

Friedenberg
(2008)

Double
blind RCT

32

18 to
75

Age 18-75,
diagnosis of
gastroparesis
within 3 months of
study, score of 27
on GCSI

Miller
(2002)

Open label
pilot study

10

1970

Idiopathic
gastroparesis
Symptoms of
nausea, vomiting,
and/or early satiety,
refractory to
prokinetic agents

Exclusion
Criteria
Presence of
esophagitis, gastric
atrophy or erosive
gastroduodenal
lesions on
endoscopy,
presence of lesions
on small bowel xray,
major abdominal
surgery,
underlying
psychiatric illness,
use of NSAIDs,
steroids, or drugs
affecting gastric acid
secretion
Pregnancy, unfit to
undergo endoscopy,
prior abdominal
surgery, known
allergy to the
protein, prior use of
botulinum toxin A,
unable to stop
medications known
to exacerbate
delayed gastric
emptying
Mechanical cause
for delayed gastric
emptying, diabetes
mellitus,
coagulopathy,
pregnant or breastfeeding

W/D

Intervention

0

Pyloric
injection of
100 units
botulinum
toxin A in 4
mL of saline

2

Pyloric
injection of
200 units (5
mL) of
Botulinum
toxin A

0

Pyloric
injection of
80-100 units
of botulinum
toxin type A

Solomon, Gastroparesis and Botulinum Toxin

6

RESULTS
Two randomized controlled trials (Arts, Friedenberg) in this systematic review
compared reported symptoms after injection botulinum toxin to placebo, while the openlabel plot study trial (Miller) compared symptoms before and after injection of botulinum
toxin.7,8,9 The study conducted by Arts et al. was a randomized controlled, double-blind
crossover study.7 All patients were randomized to receive botulinum toxin or saline first
and were analyzed in those groups.7 Twelve patients received 100 units of botulinum
toxin in 4 mL of saline and 11 patients received equal volume saline as the first
injection.7 Prior to the start of the study and four weeks after each treatment, subjects
completed the GCSI.7 In the group receiving botulinum toxin injections initially, the
GCSI decreased significantly and had a mean change from baseline of -5.6 (21.3 to
15.7).7 Four weeks later, after saline injection, no additional improvement occurred
(13.4).7 Subjects receiving initial saline injections showed significant improvement and
had a mean change from baseline of -5.8 (32.1 to 26.3).7 Further improvement followed
with botulinum toxin injections which had a mean change from baseline of -4.9 (26.3 to
21.4).7 All p-values were significant and IRULQLWLDOERWXOLQXPWR[LQLQjection, the
p-value was <0.05 and for initial saline injections followed by botulinum toxin injections,
p=0.002.7
Table 2. GCSI Scores Before and After Initial Saline Treatment
Baseline
4 weeks after initial saline 4 weeks after botulinum
injection
toxin injection
32.1
26.3
21.4
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Table 3. GCSI Scores Before and After Initial Botulinum Toxin Treatment
Baseline
4 weeks after initial
4 weeks after saline
botulinum toxin injection
injection
21.3
15.7
13.4

The study performed by Friedenberg et al. included 32 patients who were
assigned to a randomized group to receive botulinum toxin or placebo injections.8 Sixteen
patients received botulinum toxin injections and the remaining 16 received saline
injections.8 The GCSI scores were calculated before injection and one month later.8 At
the one month follow up, six of 16 (37.5%) patients randomized to botulinum toxin and
nine of 16 (56.3%) patients randomized to placebo had improvement in symptoms.8 The
relative risk benefit (RBI) was calculated to -33.3% and absolute benefit increase (ABI)
was -18.75%. Number needed to treat (NNT) was -5, meaning for every five people
treated with botulinum toxin, one person fewer will have the expected benefit. The pvalue was 0.01 in both the experimental and control group.8 Although the group receiving
botulinum toxin showed improvement in symptoms, it was not greater than the placebo
group.
Table 4. Summary of Effects of Botulinum Toxin and Placebo, One Month Post-Injection
Botulinum Toxin P-value
Placebo
P-value
Improved % *
37.5
56.3
GCSI
-6.8 + 9.2
0.01
-10.1+ 12.7
0.01
* Improvement defined as a >9-point reduction in the score of the Gastroparesis Cardinal
Symptom Index.
Table 5. Benefit of botulinum toxin on improvement of gastroparesis symptoms
Placebo
Botulinum toxin RBI
ABI
NNT
control event experimental
rate (CER)
event rate (EER)
56.25%
37.5%
-33.3%
-18.75%
-5
In the third and final study, by Miller et al., 10 patients received 80-100 units of
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botulinum toxin injections.9 Subjects completed the Gastroparesis Questionnaire before
treatment and at two- and four-week intervals post-injection.9 Overall, nine of the 10
patients had improvement in the total symptom score.9 The total symptom score had a
mean change from baseline of -5 and -6.3 at two and four weeks, respectively (15.3 to
10.3 and 9.0).9 All p-values were less than 0.05., with p=0.034 at two weeks and p=
0.006 at four weeks. As seen in Table 6, there were also significant improvements in
specific symptoms: postprandial fullness (p = 0.009), bloating (p = 0.017), and abdominal
discomfort (p= 0.042).9
Table 6. Change in symptoms to botulinum toxin injection
Symptom
Before
4 weeks after injection P
Post-prandial fullness

2.8

1.6

0.009

Post-prandial bloating

2.6

1.5

0.017

Post-prandial abdominal
discomfort
Early satiety

2.1

1.1

0.042

1.9

1.5

0.104

Post-prandial epigastric pain

1.7

1.0

0.111

Post-prandial nausea

2.2

1.3

0.068

Belching after meals

1.3

0.8

0.177

Vomiting

0.8

0.6

0.168

Total symptom score

15.3

9.1

0.006

DISCUSSION
This systematic review investigated two randomized controlled trials and one
open label pilot study to determine if botulinum toxin improves symptoms in patients
with gastroparesis. Although all of the studies demonstrated that botulinum toxin does
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improve symptoms of gastroparesis, the study by Arts et al. and Friedenberg et al.
showed that botulinum toxin was not superior to placebo.7,8 The open label pilot study by
Miller et al. revealed significant improvement in symptoms, however, there was no
placebo group for comparison.9 In addition, only patients with idiopathic gastroparesis
participated in the trial.9
As the likelihood is high that more patients will develop gastroparesis in the
future, botulinum toxin represents a possible alternative management.8 Botulinum toxin
cleaves SNAP-25, which blocks the exocytosis of acetylcholine in cholinergic nerve
endings.7 As a result, botulinum toxin can inhibit an amplified barrier function at the
pylorus and keep the pylorus open for a longer amount of time.1,7 The injection is simple
and has local nerve-blocking effects, as opposed to prokinetic agents, the current
mainstay of treatment, which have marginal benefit and significant toxicities.8
Additionally, researchers have used botulinum toxin to treat spastic disorders of
striated and smooth muscles by local injection into the muscle.8 For example, botulinum
toxin has been injected into the lower esophageal sphincter for treatment of achalasia.9
Symptoms improved temporarily for approximately three months.9
Limitations exist among the studies presented in this review. Sample sizes were
narrow; the largest number of subjects was 32, in the study by Friedenberg et al., and the
smallest number was 10, in the study by Miller et al.8,9 Future studies with a greater
population may be necessary for further evaluation. In addition, in the study by Arts et al.
and Miller et al., patients were evaluated one month after injection; a longer follow-up
period may be required to adequately assess improvement in symptoms.7,9 Another
limitation was the amount of botulinum toxin injection. In all three studies, the dose
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ranged from 80-200 units of botulinum toxin.7,8,9 Future investigations may use higher
doses to determine efficacy. Also, the open label pilot was not a blinded study, which
PD\KDYHREVWUXFWHGSDWLHQWV¶H[SHFWDWLRQVDQGthe improvement of symptoms may
represent a placebo response.
CONCLUSION
Significant improvement in symptoms of gastroparesis with botulinum toxin
injection was demonstrated in all three studies, however, in the two double blind,
randomized controlled trials, botulinum toxin did not have greater results compared to
placebo.7,8,9 Therefore, botulinum toxin does improve symptoms in patients with
gastroparesis, but the evidence does not show superiority to placebo.7,8 Future studies
should focus on adding more participants to increase the integrity and decrease
limitations of the study. Researchers may also investigate different amounts of botulinum
toxin needed to improve symptoms. Designs of future studies may use numerous
botulinum toxin injections given over several months. Improvement of symptoms can
then be better evaluated, as botulinum toxin is only a temporary nerve blocking agent and
several injections may be required to achieve maximal improvement in symptoms.
Continued research on botulinum toxin injections for the improvement of gastroparesis
symptoms is necessary to benefit patients who do not have adequate control of symptoms
with other treatment.
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